HCM
HUTCHMED (China) LtdPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Aug 17 ▲ HUTCHMED announced positive Phase III SAFFRON trial results showing…
- Sep 29 ▲ HUTCHMED announced that AstraZeneca has submitted a US NDA to the FD…
- Sep 29 ▲ HUTCHMED announced the initiation of a global Phase Ia clinical tria…
- Sep 29 ▲ AstraZeneca submitted an NDA to the FDA for ORPATHYS (savolitinib) p…
- Oct 21 ▲ HUTCHMED closed the exclusive license agreement with GSK for HMPL-A8…
- Oct 26 ▲ HUTCHMED reported positive results from two Phase III trials (SAFFRO…
- Oct 26 ▲ HUTCHMED announced positive Phase III SANOVO trial results for ORPAT…
- Oct 26 ▲ HUTCHMED announced positive Phase III SAFFRON trial results for ORPA…
- Oct 26 FDA: HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® pl…
- Oct 26 FDA: HUTCHMED Highlights SAFFRON Global Phase III Data Presente…
- Nov 2 ▲ HUTCHMED announced that regulatory filings for ORPATHYS (savolitinib…
- Nov 16 Contract: HUTCHMED Announces Expanded Coverage on National Reimburse…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 8 added (0 new), 7 trimmed or exited.
- Short sellersSTEADY
Short interest +3.9% to 275.4K shares. 7.6 days to cover, ≈0.2% of shares.
- TrendUPTREND
5% above its 50-day average.
- SocialQUIET
Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Amundi | TRIM | $2.0M |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | $1.1M |
| UBS Group AG | ADD | $973.4K |
| JPMORGAN CHASE & CO | DOUBLED | $691.2K |
| Mariner, LLC | ADD | $197.3K |
| OSAIC HOLDINGS, INC. | DOUBLED | $26.0K |
| Rockefeller Capital Management L.P. | TRIM | $10.4K |
| Arax Advisory Partners | ADD | $7.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jul 2026Price is inside the target range. Median implies +32%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jul 23, 2026 | Goldman Sachs MAINTAIN | Neutral |
| Jul 7, 2026 | B of A Securities MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Chiu Lorenso Deputy Chief Financial Officer May 20, 2026 | OTHER | 5,176 sh |
Chiu Lorenso Deputy Chief Financial Officer May 20, 2026 | OTHER | 8,863 sh |
Su Wei-guo CEO and CSO May 20, 2026 | OTHER | 132,864 sh |
Su Wei-guo CEO and CSO May 20, 2026 | OTHER | 75,140 sh |
Nixon Charles George Rupert Group General Counsel May 20, 2026 | OTHER | 7,445 sh |
Nixon Charles George Rupert Group General Counsel May 20, 2026 | OTHER | 7,644 sh |
Cheng Chig Fung Acting CEO and CFO May 20, 2026 | OTHER | 30,157 sh |
Cheng Chig Fung Acting CEO and CFO May 20, 2026 | OTHER | 26,307 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 13 press releases · 14 bullish · 0 bearish · 6 neutral- NEUTRAL PRESS RELEASENov 15, 2026
HUTCHMED announced that three of its drugs (ELUNATE, ORPATHYS, SULANDA) will continue to be…
Monitor HUTCHMED's upcoming quarterly filings for any changes in revenue trends for ELUNATE, ORPATHYS and SULANDA following the expanded NRDL coverage. The renewal removes near-term reimbursement…
- BULLISH 6-KNov 5, 2026
HUTCHMED announced that the US FDA granted Orphan Drug Designation to sovleplenib for autoimmune…
Watch for NMPA approval decisions on sovleplenib NDAs in China (primary ITP and wAIHA) and for any initiation of US clinical development for AIHA. The second orphan designation incrementally…
- BULLISH 6-KNov 2, 2026
HUTCHMED announced that regulatory filings for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib)…
Monitor EMA and MHLW review timelines and any advisory committee meetings. The US FDA NDA decision (PDUFA date) will be the next major catalyst. Also watch for potential pricing and reimbursement…
- BULLISH PRESS RELEASENov 2, 2026
HUTCHMED announced that regulatory filings for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib)…
Monitor EMA and MHLW review timelines and potential FDA action date for the US NDA. Approval in Europe and Japan would significantly expand HUTCHMED's royalty/partner revenue stream from ORPATHYS…
All HCM filing & press-release reports (33)
- PRESS-RELEASE reportNov 15, 2026
- 6-K reportNov 5, 2026
- 6-K reportNov 2, 2026
- PRESS-RELEASE reportNov 2, 2026
- 6-K reportOct 29, 2026
- 6-K reportOct 27, 2026
- 6-K reportOct 26, 2026
- PRESS-RELEASE reportOct 26, 2026
- PRESS-RELEASE reportOct 26, 2026
- 6-K reportOct 21, 2026
- 6-K reportSep 29, 2026
- 6-K reportSep 28, 2026
- PRESS-RELEASE reportSep 29, 2026
- 6-K reportSep 24, 2026
- PRESS-RELEASE reportSep 24, 2026
- 6-K reportSep 3, 2026
- 6-K reportAug 31, 2026
- 6-K reportAug 18, 2026
- 6-K reportAug 17, 2026
- PRESS-RELEASE reportAug 17, 2026
- 6-K reportJul 30, 2026
- 6-K reportJul 2, 2026
- 6-K reportJun 30, 2026
- PRESS-RELEASE reportJun 30, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 25, 2026
- PRESS-RELEASE reportJun 25, 2026
- 6-K reportJun 12, 2026
- PRESS-RELEASE reportJun 12, 2026
- PRESS-RELEASE reportApr 9, 2026
- PRESS-RELEASE reportMar 23, 2026
- PRESS-RELEASE reportMar 5, 2026
- PRESS-RELEASE reportMar 4, 2026